NCT07282769

Semaglutide (Wegovy) Treatment for Trichotillomania

Once Weekly Semaglutide Treatment of Trichotillomania: An Open-Label Study

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: University of Chicago · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This research study is testing the effectiveness and safety of semaglutide (Wegovy) in people with trichotillomania, also known as hair-pulling disorder.

Detailed description

The goal of the proposed study is to evaluate the efficacy and safety of semaglutide in individuals with trichotillomania. The hypothesis to be tested is that semaglutide will reduce urges to pull hair and pulling behavior and will be well tolerated in participants with trichotillomania. The proposed study will provide needed pilot data on the treatment of a disabling disorder that currently lacks available options for pharmacological treatment. The investigators will conduct an open-label pharmacotherapy trial in 10 individuals with trichotillomania. Participants with trichotillomania will be started and continued on medication during an 8-week treatment phase. The study will be the first to use a once weekly Glucagon-like peptide 1 (GLP-1) receptor agonist pharmacological intervention to target urges in trichotillomania and thereby has the potential to set a new standard of care for a range of compulsive behaviors.

Conditions

• Trichotillomania (Hair-Pulling Disorder)
• Trichotillomania
• Hair Pulling Disorder
• Hair Pulling
• Hair-Pulling Disorder

Interventions

Type	Name	Description
DRUG	Semaglutide	All participants in the study will receive semaglutide (Wegovy).

Timeline

• Start date: 2026-02-01
• Primary completion: 2027-02-01
• Completion: 2027-02-01
• First posted: 2025-12-15
• Last updated: 2025-12-17

Regulatory

• FDA-regulated drug study